Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2023

In 2023, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 14.36% of shares outstanding on 13 Jan 2023 to 9.01% on 29 Dec 2023, a change of -5.35 percentage points. The year's high was 20.81% on 31 Mar 2023 and its low 8.01% on 15 Nov 2023, averaging 13.45% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.79 days on 28 Feb 2023. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2023

2023 in figures

Start of year
14.36% (13 Jan 2023)
End of year
9.01% (29 Dec 2023)
Change
-5.35 pp
High
20.81% (31 Mar 2023)
Low
8.01% (15 Nov 2023)
Average
13.45%
Highest days to cover
19.79 (28 Feb 2023)
SEC filings marked
8

Every report in 2023

Atara Biotherapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202314.36%11.92
31 Jan 202314.79%13.58
15 Feb 202314.60%14.4410-K filed, results (8-K)
28 Feb 202314.67%19.79
15 Mar 202317.41%11.50
31 Mar 202320.81%13.32
14 Apr 202320.03%16.28
28 Apr 202318.55%14.00
15 May 202314.47%7.8110-Q filed, results (8-K)
31 May 202312.88%6.43
15 Jun 202313.48%5.74
30 Jun 202311.94%4.03
14 Jul 202312.88%9.39
31 Jul 202313.22%12.41
15 Aug 202312.06%9.5210-Q filed, results (8-K)
31 Aug 202311.40%8.98
15 Sep 202311.54%17.39
29 Sep 202311.41%8.65
13 Oct 202312.14%9.24
31 Oct 202312.25%12.30
15 Nov 20238.01%1.0010-Q filed, results (8-K)
30 Nov 202310.90%1.54
15 Dec 20239.94%4.24
29 Dec 20239.01%1.85

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.